コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 the activation of C5, and thus the terminal complement pathway.
2 any components of the classical and terminal complement pathway.
3 in determining appropriate activation of the complement pathway.
4 odies occurs primarily through the classical complement pathway.
5 ecruit natural IgM to initiate the classical complement pathway.
6 ectin protein is the activator of the lectin complement pathway.
7 ich renders them incapable of activating the complement pathway.
8 adhesion of leukocytes and activation of the complement pathway.
9 ating activation of the classical arm of the complement pathway.
10 to affect the antimicrobial activity of this complement pathway.
11 ants that directly influence the alternative complement pathway.
12 uction, followed by global activation of the complement pathway.
13 s that link glioma pathogenesis with the MBL complement pathway.
14 d C1q and act as inhibitors of the classical complement pathway.
15 to protect Ad5 from attack by the classical complement pathway.
16 bility to normalize activity of the terminal complement pathway.
17 as mediated by natural IgM and the classical complement pathway.
18 mediated by dysregulation of the alternative complement pathway.
19 tients with dysregulation of the alternative complement pathway.
20 ciated with dysregulation of the alternative complement pathway.
21 hese heparinoids can control the alternative complement pathway.
22 t, in part, on activation of the alternative complement pathway.
23 uncontrolled stimulation of the alternative complement pathway.
24 n of a rate-limiting step in the alternative complement pathway.
25 ection, suggesting a defect in the classical complement pathway.
26 suggested an important role for the terminal complement pathway.
27 otic cells, thereby activating the classical complement pathway.
28 (Cfh) is a key regulator of the alternative complement pathway.
29 to C3b signals the start of the alternative complement pathway.
30 erum, an essential component of the terminal complement pathway.
31 livary proteins that inhibit the alternative complement pathway.
32 e lptA mutant occurred through the classical complement pathway.
33 ng therapeutic with selectivity for a single complement pathway.
34 tense genetic and functional analysis of the complement pathway.
35 innate immunity and activator of the lectin complement pathway.
36 ost fluid-phase regulator of the alternative complement pathway.
37 seems to occur primarily via the alternative complement pathway.
38 was mediated by activation of the classical complement pathway.
39 r H (fH), a key regulator of the alternative complement pathway.
40 riggered activation of C1q and the classical complement pathway.
41 ot of downstream components of the classical complement pathway.
42 I and FcgammaRII and activates the classical complement pathway.
43 ading opsonophagocytosis and the alternative complement pathway.
44 /-), an essential protein in the alternative complement pathway.
45 phils but failed to activate the alternative complement pathway.
46 o contact with components of the alternative complement pathway.
47 initiation of the activation of alternative complement pathway.
48 generation drugs that target the alternative complement pathway.
49 tor 1q (C1q) and activation of the classical complement pathway.
50 the dominant Ig and proteins of the classic complement pathway.
51 ericidal activity of NHS via the alternative complement pathway.
52 n ( approximately 65 kDa) is a member of the complement pathway.
53 d RPE cells, particularly with regard to the complement pathway.
54 ia as well as PRMs and enzymes of the lectin complement pathway.
55 h IgM indicating activation of the classical complement pathway.
56 omplex dependent activation of the classical complement pathway.
57 anosomes limit the action of the alternative complement pathway.
58 the activation and fixation of the classical complement pathway.
59 C1s of the first component of the classical complement pathway.
60 C1q fixation and activation of the classical complement pathway.
61 vated both the classical and the alternative complement pathways.
62 not saprophytic Leptospira inhibit the three complement pathways.
63 e classical and lectin (but not alternative) complement pathways.
64 eby inhibiting the classical and alternative complement pathways.
65 to trigger classical as well as alternative complement pathways.
66 ive therapeutics that harness the potency of complement pathways.
67 ing antibody engagement, but not late-acting complement pathways.
68 by inhibiting the classical and alternative complement pathways.
69 on of both the classical and the alternative complement pathways.
70 obody, hC3Nb2, inhibits C3 deposition by all complement pathways.
71 in both diseases, including inflammasome and complement pathways.
72 molecules (PRMs) of the classical and lectin complement pathways.
73 binds to C3, resulting in suppression of all complement pathways.
74 Mirolysin exhibited a strong effect on all complement pathways.
76 associates with a negative regulator of the complement pathway, a likely mechanism for immune evasio
77 with the recognition proteins of the lectin complement pathway, a recombinant fragment encompassing
78 ruses are potent activators of extracellular complement pathways, a first line of defense that viruse
79 eat inactivation, as well as by the terminal complement pathway Ab eculizumab, the purinergic P2 rece
80 rs showed significant reduction in classical complement pathway activation and decreased levels of tu
82 hat C1q induction and classic or alternative complement pathway activation do not contribute signific
86 BL-C, are involved in the Aspergillus-lectin complement pathway activation rather than ficolin-A.
87 red CML and to force a switch from classical complement pathway activation to C1q-dependent alternati
88 Given these results, we conclude that lectin complement pathway activation triggered by ligand-CL-11
92 ccumulating evidence suggests a dysregulated complement pathway among the pathogenic processes of sch
93 olymorphisms (SNPs) in 9 genes in the lectin complement pathway and 3 additional SNPs in MBL2 were te
95 ich may themselves influence the alternative complement pathway and are contained within a common del
97 ne expression of factor B of the alternative complement pathway and C3 in mouse middle ear epithelium
99 OR, 2.17; 95% CI, 1.12-4.24; P = 0.023), the complement pathway and calcified drusen (OR, 3.75; 95% C
100 onnection between the inflammatory classical complement pathway and connective tissue homeostasis.
101 es of ischemic stress, activating the lectin complement pathway and directing the innate immune respo
102 q protein, thereby attenuating the classical complement pathway and facilitating pneumococcal complem
103 fluid-phase dysregulation of the alternative complement pathway and frequently deviates from the clas
104 complement factor D controls the alternative complement pathway and generation of complement componen
105 y level, there were associations between the complement pathway and geographic atrophy (GA) (OR, 2.17
107 re-establishes regulation of the alternative complement pathway and provide support for a limited tri
108 Uncontrolled activation of the alternative complement pathway and secretion of vascular endothelial
110 ina involves the activity of the alternative complement pathway and that eliminating the alternative
112 nt knowledge about the main functions of the complement pathways and the involvement of complement in
113 proteases required to activate the classical complement pathway, and C3 showed a significant age-depe
114 ent factor H, a regulator of the alternative complement pathway, and LOC387715/HtrA1 are the most con
115 ding to a strong activation of the classical complement pathway, and results in consumption of comple
116 ing CRP-mediated activation of the classical complement pathway, and that the characteristic of CRP t
117 acute-phase response signaling pathway, the complement pathway, and the coagulation pathway are diff
119 activated both the classical and alternative complement pathways, and C1q was found to be crucial for
120 within the PIV5 F protein, the activation of complement pathways, and subsequent complement-mediated
121 to AMR-triggered activation of the classical complement pathway, antibody-dependent cellular cytotoxi
122 at all-trans-retinal (atRal) and alternative complement pathway (AP) activation contribute to RPE cel
124 Uncontrolled activation of the alternative complement pathway (AP) is thought to be associated with
125 role in the amplification of the alternative complement pathway (AP) of the innate immune system.
126 irulence, the molecular basis of alternative complement pathway (AP) regulation by meningococcal CPSs
129 As such, selective targeting of pro-allergic complement pathways appears an attractive therapeutic op
131 study was designed to determine which of the complement pathways are activated during acute pneumococ
132 cate that both the classical and alternative complement pathways are critical for middle ear immune d
133 encodes a major inhibitor of the alternative complement pathway, are associated with the risk for dev
134 H (FH), a major regulator of the alternative complement pathway, are associated with various diseases
135 gene screens have identified members of the complement pathway as contributing to the risk of AMD.
136 zation of activity levels of the alternative complement pathway as measured by C3/C3d ratios and C3Ne
138 of complement activity, acting on all three complement pathways as a membrane-bound receptor of C3b/
139 g in increased activation of the alternative complement pathway, as a key component of disease biolog
140 is most evident in changes of interferon and complement pathways, as well as neutrophil-associated si
141 xpress and release protein components of the complement pathways, as well as secreting and anchoring
143 ed that cell-bound CL-11 required the lectin complement pathway-associated protease MASP-2 to trigger
144 ypothesized that activation of the classical complement pathway at the endothelial cell surface by HL
145 A (siRNA) against C5, which is formed by all complement pathways, attenuated murine ChP inflammation,
146 its serum antibodies that activate classical complement pathway bacteriolysis and also inhibit bindin
148 though immunosuppressive agents and terminal complement pathway blockers are helpful in some patients
149 in eukaryotic cells activated the classical complement pathway but not the alternative or lectin pat
150 Modified forms of LDL activate the classical complement pathway, but no lectin pathway activation was
151 b against C3b that inhibited the alternative complement pathway, but not the classical pathway, was d
152 C activate the classical and the alternative complement pathways, but the role of the lectin pathway
153 Treatment of purified NiV with NHS activated complement pathways, but there was very little C3 deposi
154 osylated IgG is related to activation of the complement pathway by mannose-binding lectin, as suggest
155 (FI) is a serine protease that inhibits all complement pathways by degrading activated complement co
157 f LTB4 in IC-ALI and activation of C5 by the complement pathway C5 convertase rather than by non-C pr
158 s indicated that activation of the classical complement pathway (CCP) was a primary mechanism for spo
159 ated through activation of each of the three complement pathways (classical, alternative, and lectin)
160 reted proteins involved in regulation of the complement pathway (clusterin, vitronectin, and fibromod
161 both of which encode proteins in the lectin complement pathway (collectin kidney 1 (CL-K1) and MASP-
162 hat genetic variation within early classical complement pathway components (C1q, C1r, and C1s) could
163 croglia and find selective downregulation of complement pathway components with microglia inhibition,
164 hat the alternative pathway was not the only complement pathway contributing to protection against di
168 inopathy (OIR), we observed that alternative complement pathway-deficient mice (Fb(-/-)) exhibited a
169 e identified metabolites and activity of the complement pathway (defined by the C3d-to-C3 ratio) were
172 We investigated the role of the alternative complement pathway during the formation and resolution o
173 C3 plasma values could reflect a more severe complement pathway dysfunction than in AMD, leading to e
174 tivated neutrophils activate the alternative complement pathway, establishing an inflammatory amplifi
175 ether, these findings demonstrate a role for complement pathway factors in fundamental developmental
176 ormal functional properties of the classical complement pathway followed by reduced severity of SLE s
177 sen formation, COL4 accumulation in ECM, and complement pathway gene alteration, it impacted the comp
179 ement component C4 (C4) is a highly variable complement pathway gene situated approximately 500 kb fr
182 of its amplifying property, the alternative complement pathway has been implicated in a number of in
183 racteristic of CRP to activate the classical complement pathway has no role in protecting mice from i
185 early components of the classical and lectin complement pathways have been shown to protect low-densi
186 g lectin gene, a key activator in the lectin complement pathway, have been associated with risk of se
188 nt pathways) or CR2-fH (inhibits alternative complement pathway) immediately posttransplantation.
189 nction and key components of the alternative complement pathway in a series of critically ill patient
190 l model that can be used to study the lectin complement pathway in acute and chronic models of human
191 FD) was generated to inhibit the alternative complement pathway in advanced dry age-related macular d
192 d sufficient for inhibition of the classical complement pathway in all patients, as measured by CH50.
196 ficiency of FHL-1, the main regulator of the complement pathway in BrM, where drusen develop, is an i
197 An enrichment of rare pLoF variants in the complement pathway in cases versus controls (OR, 2.94; 9
198 us, to investigate the role of the classical complement pathway in contusion-induced SCI, male C1q kn
199 Together, our data implicate the alternative complement pathway in facilitating neovessel clearance b
202 gest a modest involvement of the alternative complement pathway in targeting vessels for regression i
203 e is known about the role of the alternative complement pathway in the initial vascular regression ph
205 ing further underscores the influence of the complement pathway in the pathogenesis of this disease.
206 Increased activation of the alternative complement pathway in vitreous was controlled by disease
208 CAIA) model, in which the AP is unique among complement pathways in being both necessary and sufficie
209 tion samples showed upregulation of multiple complement pathways in patients with TMA who had gene va
213 inhibited classical, lectin and alternative complement pathways in vitro when added in excess to hum
216 ance by recruiting factor H (FH; alternative complement pathway inhibitor) and also by limiting class
217 everal gonococcal strains bind the classical complement pathway inhibitor, C4b-binding protein (C4BP)
218 r for complement activation, the predominant complement pathway involved, or its role in the pathogen
220 he first step of activation of the classical complement pathway involves the binding of the globular
222 and selective inhibition of the alternative complement pathway is an effective treatment of murine l
228 C1q, the first component of the classical complement pathway, is also a pattern recognition recept
230 The secondary aims were to determine which complement pathways lead to C4d deposition and to determ
231 region of C1q and to initiate the classical complement pathway, leading to activation of C4 and C3,
232 C1q bound to apoptotic cells, activated the complement pathway, leading to C3b deposition, and enhan
238 s a key role in the activation of the lectin-complement pathway of innate immunity, and its deficienc
239 ents kill serum-resistant E. coli though the complement pathway of the innate immune system, suggesti
240 sted ex vivo the activation of the classical complement pathway on ICL CD4+ T cells.RESULTSAll ICL pa
241 t C4b deposition on live bacteria (classical complement pathway), only those antibodies that inhibite
243 e injection of either CR2-Crry (inhibits all complement pathways) or CR2-fH (inhibits alternative com
244 saline, CR2-fH, CR2-Crry (which inhibits all complement pathways), or soluble CR2 (sCR2; C3d-binding
246 had increased activation of the alternative complement pathway (P = 0.003) and elevated levels of co
247 that requires activation of the alternative complement pathway, passive transfer of antibodies to mo
248 , these data suggest that MBL and the lectin complement pathway play a significant role in vascular d
249 eding success, suggesting that CSMD1 and the complement pathway play an important role in the normal
250 examine recent evidence that the alternative complement pathway plays a key and, in most instances, o
252 of the alternative rather than the classical complement pathway, previously not appreciated for IFTA,
253 hway (n = 22) and integrated these data with complement pathway protein data already available on the
259 mplement factor H (CFH), a major alternative complement pathway regulator, are associated with the de
260 g factor H (FH), which is a main alternative complement pathway regulatory protein, have been well ch
261 an however activate the classical and lectin complement pathways, rendering this species still vulner
262 ponse and that activation of the alternative complement pathway represents one of the innate immune d
263 molytic uremic syndrome, blocks the terminal complement pathway required for serum bactericidal activ
266 ) is known to form complexes with the lectin complement pathway serine proteases MASP-1 and MASP-2.
267 gococcal vaccine antigen, activate classical complement pathway serum bactericidal activity (SBA) and
268 C3a complement receptor (C3aR), alternative complement pathway signaling, and antioxidant therapy.
270 bit IgM-mediated activation of the classical complement pathway, since survival of the tspB triple kn
271 by NHS was not due to a global inhibition of complement pathways, since complement was found to signi
272 y disease stage and genetic variation in the complement pathway, supporting a role for complement act
273 e found that despite being recognized by all complement pathways, T. forsythia is resistant to killin
274 fluid-phase dysregulation of the alternative complement pathway that leads to deposition of complemen
275 he spontaneous activation of the alternative complement pathway that occurs after the genetic absence
276 ity of ficolin-2, an initiator of the lectin complement pathway that was previously shown to bind ST1
277 is a well known inhibitor of the alternative complement pathway, the functions of the CFHR proteins a
278 KE are not associated with activation of the complement pathway, the only other identified cause of t
279 While linked to genetic polymorphisms in the complement pathway, there are many individuals with high
280 self components, and triggers the classical complement pathway through activation of its associated
281 N. gonorrhoeae is mediated by the classical complement pathway through an antibody-dependent mechani
282 ains and to trigger activation of the lectin complement pathway through associated serine proteases.
285 gated BSA triggered activation of the lectin complement pathway, thus further supporting the hypothes
286 phoinositide signalling works in tandem with complement pathways to regulate the activity of Star-PAP
287 prevent complement activation and steer the complement pathway toward generation of inactivated C3b
288 itis result from activation of the classical complement pathway triggered by direct binding of C1q to
289 We found that activation of the classical complement pathway up to C5 was sufficient to neutralize
291 ndicate that ethanol activates the classical complement pathway via C1q binding to apoptotic cells in
292 ata suggest that initiation of the classical complement pathway via C1q is detrimental to recovery af
293 antibodies gain the capacity to activate the complement pathway via mannose-binding lectin (MBL), whi
296 suggesting that activation of the classical complement pathway was not required for innate immunity.